Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 15278017)

1.

Drug development for anxiety disorders: new roles for atypical antipsychotics.

Carson WH, Kitagawa H.

Psychopharmacol Bull. 2004 Winter;38(1):38-45.

PMID:
15278017
2.

Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Pae CU, Serretti A, Patkar AA, Masand PS.

CNS Drugs. 2008;22(5):367-88. Review.

PMID:
18399707
3.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
4.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
5.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
6.

Unmet needs in the treatment of anxiety disorders.

Pollack MH.

Psychopharmacol Bull. 2004 Winter;38(1):31-7.

PMID:
15278016
7.

Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.

Katzman MA.

J Affect Disord. 2011 Jan;128 Suppl 1:S11-20. doi: 10.1016/S0165-0327(11)70004-0. Review.

PMID:
21220076
8.

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.

Gao K, Muzina D, Gajwani P, Calabrese JR.

J Clin Psychiatry. 2006 Sep;67(9):1327-40. Review.

PMID:
17017818
9.

Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

Celada P, Bortolozzi A, Artigas F.

CNS Drugs. 2013 Sep;27(9):703-16. doi: 10.1007/s40263-013-0071-0. Review.

PMID:
23757185
10.

Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.

Bruins Slot LA, Bardin L, Auclair AL, Depoortere R, Newman-Tancredi A.

Behav Pharmacol. 2008 Mar;19(2):145-52. doi: 10.1097/FBP.0b013e3282f62cb2.

PMID:
18332679
11.

Review of atypical antipsychotics in anxiety.

Vulink NC, Figee M, Denys D.

Eur Neuropsychopharmacol. 2011 Jun;21(6):429-49. doi: 10.1016/j.euroneuro.2010.12.007. Epub 2011 Feb 22. Review.

PMID:
21345655
12.

Use of atypical antipsychotics in refractory depression and anxiety.

Nemeroff CB.

J Clin Psychiatry. 2005;66 Suppl 8:13-21. Review.

PMID:
16336032
13.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

PMID:
14994733
14.

Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Swainston Harrison T, Perry CM.

Drugs. 2004;64(15):1715-36. Review.

PMID:
15257633
15.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
16.

Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.

Egashira N, Okuno R, Matsushita M, Abe M, Mishima K, Iwasaki K, Nishimura R, Oishi R, Fujiwara M.

Eur J Pharmacol. 2008 Sep 11;592(1-3):103-8. doi: 10.1016/j.ejphar.2008.06.100. Epub 2008 Jul 4.

PMID:
18644366
17.

Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.

Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.

Clin Ther. 2013 Dec;35(12):1867-75. doi: 10.1016/j.clinthera.2013.09.006. Epub 2013 Oct 8.

19.

Serotonin receptors: their key role in drugs to treat schizophrenia.

Meltzer HY, Li Z, Kaneda Y, Ichikawa J.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. Review.

PMID:
14642974
20.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

PMID:
14640142
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk